Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.
about
Killing cancer cells by targeted drug-carrying phage nanomedicinesAntibody-DM1 conjugates as cancer therapeutics.Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release.Fibroblast growth factors in cancer: therapeutic possibilities.Overcoming multidrug resistance in taxane chemotherapy.Thermal and pH Sensitive Multifunctional Polymer Nanoparticles for Cancer Imaging and TherapyAdvanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Use of fluorine in the medicinal chemistry and chemical biology of bioactive compounds--a case study on fluorinated taxane anticancer agents.Tumor-targeting drug delivery of new-generation taxoids.Targeted imaging and therapy of brain cancer using theranostic nanoparticlesscFv antibody: principles and clinical applicationTargeted drug delivery in cancer therapy.Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.Antibody-cytotoxic agent conjugates for cancer therapy.In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer.Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug deliveryImproved biochemical strategies for targeted delivery of taxoidsNanotechnology for targeted cancer therapy.Exploration of fluorine chemistry at the multidisciplinary interface of chemistry and biology.Thermoresponsive Collagen/Cell Penetrating Hybrid Peptide as Nanocarrier in Targeting-Free Cell Selection and Uptake.Role of nanocarrier systems in cancer nanotherapy.Cancer immunotherapy and nanomedicine.Analytical methods for physicochemical characterization of antibody drug conjugatesOptimising the delivery of tubulin targeting agents through antibody conjugation.Immunoconjugates and long circulating systems: origins, current state of the art and future directionsDrug-conjugated antibodies for the treatment of cancer.Nanoparticulate carriers: an emerging tool for breast cancer therapy.Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice?The anti-cancer potency and mechanism of a novel tumor-activated fused toxin, DLM.A fluorescence off-on reporter for real time monitoring of gemcitabine delivery to the cancer cells.Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.Protein based therapeutic delivery agents: Contemporary developments and challenges.HPMA-copolymer conjugates targeted to tumor endothelium using synthetic oligopeptides.Renal Clearable Organic Nanocarriers for Bioimaging and Drug DeliveryAn enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates.Anti-EGFR-iRGD recombinant protein conjugated silk fibroin nanoparticles for enhanced tumor targeting and antitumor efficiency.Novel Taxoid-Based Tumor-Targeting Drug Conjugates.Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell lines in vitro and in vivo.Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
P2860
Q21256651-F3995BAC-332F-43C0-854D-8DB337395DD1Q34177359-167A3EDF-42CD-445B-80E6-17A2AB5FDA8BQ34565264-58EA26FD-1C10-4B43-A63D-2F944398C5AFQ34837255-F40989E7-366A-44E3-B962-EF6728B39BE1Q34999208-6362FA87-FB65-4FA4-9C02-5B04D0A96815Q35202143-5DEFB5B2-D79E-4EA4-A3D4-04EB12B008F4Q35376573-7E7310DC-5D74-453E-87E6-037EC17A5085Q35459059-19D44240-75F1-499D-9D14-D309949A9B34Q35762544-CE23C960-4E4F-4612-96A7-F3843ECC7CD1Q35765100-A81F9479-438B-4590-8B3A-6C75EBF37D7FQ35792897-0F5D930C-1891-490E-B7EE-54948A119282Q35852647-470059B3-4E1E-41C1-800C-F266276BD316Q36200150-532C5DD6-5C7A-4BAB-BCD2-C50CCB47E615Q36200153-3A46B883-3C06-497E-9658-0C82772E0D3CQ36316831-6E5ED3E3-F15C-4BC4-88E1-C4EB3F08B46CQ36407249-C23033C7-9CC2-40E4-BB5E-EA8947A1290DQ36544167-4786B069-7A10-4791-BFA6-310B4A4BA379Q36642502-480E0F91-0EB8-4964-B930-EB7C5CE92DA5Q36842770-615C5955-3715-463D-91CE-9699C4A3BD49Q37118460-A5F5F839-AB78-4C27-8804-50B9BB9C45FAQ37525095-68D893C6-B432-4235-AAFF-70CA190D0FBBQ37622867-F3FF80E9-9710-4947-83DE-E2E536EE53FFQ37785836-5B6283BD-3506-4EE6-B8B8-7512A521C49DQ37858385-20DAF72C-9A45-4123-9196-BCD103919B36Q38024991-AE77B192-4744-4F10-A902-1E759E143F9BQ38042256-0EE89F74-B83C-490E-9BDA-20A25D9AE2D3Q38061647-5938033C-4113-45BD-B9AF-92A4A4C44989Q38250517-173B23E7-0710-427B-9324-B4B48B36B596Q38806793-97B5EB3C-C98C-4DC0-A484-68551AC314F3Q38912309-E7D00D41-640F-49C2-A226-79CEAB28DAA2Q39129321-6B208C10-DB2E-4751-85DB-4E3BBD5461DDQ39210427-0A30CE41-9B40-4434-AA26-A881AD26439FQ39273739-09A8E9A8-2B63-4416-A64D-0080FAC799F6Q39782523-9496C34C-BF5C-4694-BA0C-6077C28A12B6Q41628739-D693B783-B3AD-4C3C-A36B-A8EA2D93327CQ41829276-F651F127-0315-4829-B4ED-910C64462FB1Q42082847-EFF256FF-03DB-43C8-9B7D-FA055101DB92Q42087874-E4ECAF1C-AB1F-4531-8C22-34DB15A54FB5Q43606520-89362B49-390A-4BA5-9431-5CF39937AA9AQ52582168-29607FDF-9E9B-4835-BD02-2B4BF57F8E3E
P2860
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.
@ast
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.
@en
type
label
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.
@ast
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.
@en
prefLabel
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.
@ast
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.
@en
P1476
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.
@en
P2093
P304
P356
10.1016/S0169-409X(97)00095-1
P407
P577
1998-04-01T00:00:00Z